Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.64 |
| ▸ | MMP12 | P39900 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MMP8 | P22894 | 1/20 | 0.64 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244911 | 0.93 | ADAMTS5 (0.57) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL4363825 | 0.93 | ADAMTS5 (0.75) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2254049 | 0.90 | ADAMTS5 (0.60) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2243910 | 0.88 | ADAMTS5 (0.56) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2248253 | 0.88 | HPGDS (0.53) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2247514 | 0.88 | ADAMTS5 (0.81) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2247091 | 0.86 | MMP12 (0.65) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2249785 | 0.85 | ADAMTS5 (0.58) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2247372 | 0.84 | ADAMTS5 (0.64) | ADAMTS5MMP12MMP2MMP8ADAMTS4 | |
| SCHEMBL2247520 | 0.84 | ADAMTS5 (0.72) | ADAMTS5MMP12MMP2MMP8ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | ADAMTS5 1/4885MMP12 54/4885MMP2 49/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | ADAMTS5 1/4885MMP12 54/4885MMP2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.